Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Future perspectives in melanoma research "Melanoma Bridge", Napoli, November 30th-3rd December 2016

Research output: Contribution to journalJournal articleResearchpeer-review

  1. A narrative review of new treatment options for chronic kidney disease in type 2 diabetes

    Research output: Contribution to journalReviewResearchpeer-review

  2. Troubleshooting in advanced VATS procedures

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Experimental non-alcoholic steatohepatitis in Göttingen Minipigs: consequences of high fat-fructose-cholesterol diet and diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. The capacity of CD4+ Vγ9Vδ2 T cells to kill cancer cells correlates with co-expression of CD56

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Vγ9Vδ2 T Cells Concurrently Kill Cancer Cells and Cross-Present Tumor Antigens

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. TAM Receptor Inhibition-Implications for Cancer and the Immune System

    Research output: Contribution to journalReviewResearchpeer-review

  4. Adrenergic Signaling in Immunotherapy of Cancer: Friend or Foe?

    Research output: Contribution to journalReviewResearchpeer-review

  • Paolo A Ascierto
  • Sanjiv S Agarwala
  • Gennaro Ciliberto
  • Sandra Demaria
  • Reinhard Dummer
  • Connie P M Duong
  • Soldano Ferrone
  • Silvia C Formenti
  • Claus Garbe
  • Ruth Halaban
  • Samir Khleif
  • Jason J Luke
  • Lluis M Mir
  • Willem W Overwijk
  • Michael Postow
  • Igor Puzanov
  • Paul Sondel
  • Janis M Taube
  • Per Thor Straten
  • David F Stroncek
  • Jennifer A Wargo
  • Hassane Zarour
  • Magdalena Thurin
View graph of relations

Major advances have been made in the treatment of cancer with targeted therapy and immunotherapy; several FDA-approved agents with associated improvement of 1-year survival rates became available for stage IV melanoma patients. Before 2010, the 1-year survival were quite low, at 30%; in 2011, the rise to nearly 50% in the setting of treatment with Ipilimumab, and rise to 70% with BRAF inhibitor monotherapy in 2013 was observed. Even more impressive are 1-year survival rates considering combination strategies with both targeted therapy and immunotherapy, now exceeding 80%. Can we improve response rates even further, and bring these therapies to more patients? In fact, despite these advances, responses are heterogeneous and are not always durable. There is a critical need to better understand who will benefit from therapy, as well as proper timing, sequence and combination of different therapeutic agents. How can we better understand responses to therapy and optimize treatment regimens? The key to better understanding therapy and to optimizing responses is with insights gained from responses to targeted therapy and immunotherapy through translational research in human samples. Combination therapies including chemotherapy, radiotherapy, targeted therapy, electrochemotherapy with immunotherapy agents such as Immune Checkpoint Blockers are under investigation but there is much room for improvement. Adoptive T cell therapy including tumor infiltrating lymphocytes and chimeric antigen receptor modified T cells therapy is also efficacious in metastatic melanoma and outcome enhancement seem likely by improved homing capacity of chemokine receptor transduced T cells. Tumor infiltrating lymphocytes therapy is also efficacious in metastatic melanoma and outcome enhancement seem likely by improved homing capacity of chemokine receptor transduced T cells. Understanding the mechanisms behind the development of acquired resistance and tests for biomarkers for treatment decisions are also under study and will offer new opportunities for more efficient combination therapies. Knowledge of immunologic features of the tumor microenvironment associated with response and resistance will improve the identification of patients who will derive the most benefit from monotherapy and might reveal additional immunologic determinants that could be targeted in combination with checkpoint blockade. The future of advanced melanoma needs to involve education and trials, biobanks with a focus on primary tumors, bioinformatics and empowerment of patients and clinicians.

Original languageEnglish
JournalAnnals of Translational Medicine
Volume15
Issue number1
Pages (from-to)236
ISSN1479-5876
DOIs
Publication statusPublished - 16 Nov 2017

    Research areas

  • Journal Article

ID: 52221569